Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Friday September 05, 2025

The +securities to be quoted are:

+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	37,949	08/09/2025

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type	**Registration number**
ACN	616620369

1.3 ASX issuer code

TLX

1.4 The announcement is
New announcement

1.5 Date of this announcement

5/9/2025

Part 2 - Type of Issue

2.1 The +securities to be quoted are:
+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

2.2 The +class of +securities to be quoted is:
Additional +securities in a class that is already quoted on ASX ("existing class")

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class issued under an +employee incentive scheme

FROM (Existing Class)
ASX +security code and description

No security currently exists

FROM (Existing Class)
+Security description

No security currently exists

TO (Existing Class)
ASX +security code and description

TLX : ORDINARY FULLY PAID

Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

13,793

Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Shares allocated to Australian employees under the Telix Employee Share Purchase Plan (ESPP) for the inaugural three month contribution period (April to June 2025, inclusive). Refer to Equity Incentive Plan Rules at https://ir.telixpharma.com/governance/documents-charters.

Are any of these +securities being issued to +key management personnel (KMP) or an +associate
Yes

Provide details of the KMP or +associates being issued +securities

Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	1,096

Issue date

8/9/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Issue details

Number of +securities to be quoted

13,793

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 12.16350000

Any other information the entity wishes to provide about the +securities to be quoted

Participation in the ESPP (with a maximum pre-tax salary contribution of AU$40,000 per calendar year) is available to eligible Australian employees for applicable contribution periods. For the inaugural three month contribution period (April to June 2025, inclusive), participating employees will receive shares at a 15% discount from the lower of the Telix share price as at close of trade on 1 April and 2 September 2025. Shares allocated will be restricted from trade or transfer until April 2027.

Additional +securities to be quoted in an existing class issued under an +employee incentive scheme

FROM (Existing Class)
ASX +security code and description

No security currently exists

FROM (Existing Class)
+Security description

No security currently exists

TO (Existing Class)
ASX +security code and description

TLX : ORDINARY FULLY PAID

Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

24,156

Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Shares issued which will be distributed to the Telix US depository bank and allocated to US employees as American Depository Shares (ADS) under the Telix US Employee Stock Purchase Plan (US ESPP) for the inaugural three month contribution period (April to June 2025, inclusive). Refer to US ESPP Rules within Telix 2024 US Annual Report (on Form 20-F) at https://ir.telixpharma.com/filings/sec-filings and 2025 AGM Notice of Meeting at https://ir.telixpharma.com/reports.

Are any of these +securities being issued to +key management personnel (KMP) or an +associate

No

Issue date

8/9/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

24,156

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?	**What is the issue price per +security?**
USD - US Dollar	USD 8.01550000

Any other information the entity wishes to provide about the +securities to be quoted

Participation in the US ESPP (with a maximum post-tax salary contribution of US$25,000 per calendar year) is available to eligible US employees for applicable contribution periods. For the inaugural three month contribution period (April to June 2025, inclusive), participating employees receive ADS at a 15% discount from the lower of the Telix ADS price as at close of trade on 1 April and 2 September 2025. ADS allocated will be restricted from trade or transfer until April 2027.

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,437,008

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,373,000
TLXAO : SHARE APPRECIATION RIGHTS	15,264,300
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37	242,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	10,342
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	2,881,250
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38	289,225
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000

Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?
Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13